AU2012294342B2 - Methods and compositions for the treatment of autoimmune and inflammatory diseases - Google Patents

Methods and compositions for the treatment of autoimmune and inflammatory diseases Download PDF

Info

Publication number
AU2012294342B2
AU2012294342B2 AU2012294342A AU2012294342A AU2012294342B2 AU 2012294342 B2 AU2012294342 B2 AU 2012294342B2 AU 2012294342 A AU2012294342 A AU 2012294342A AU 2012294342 A AU2012294342 A AU 2012294342A AU 2012294342 B2 AU2012294342 B2 AU 2012294342B2
Authority
AU
Australia
Prior art keywords
antibody
rhob
seq
inflammatory
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012294342A
Other languages
English (en)
Other versions
AU2012294342A1 (en
Inventor
James DUHADAWAY
Lisa Laury-Kleintop
Laura Mandik-Nayak
George C. Prendergast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lankenau Institute for Medical Research
Original Assignee
Lankenau Institute for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lankenau Institute for Medical Research filed Critical Lankenau Institute for Medical Research
Publication of AU2012294342A1 publication Critical patent/AU2012294342A1/en
Application granted granted Critical
Publication of AU2012294342B2 publication Critical patent/AU2012294342B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2012294342A 2011-08-10 2012-08-09 Methods and compositions for the treatment of autoimmune and inflammatory diseases Active AU2012294342B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161522009P 2011-08-10 2011-08-10
US61/522,009 2011-08-10
PCT/US2012/050146 WO2013023059A2 (en) 2011-08-10 2012-08-09 Methods and compositions for the treatment of autoimmune and inflammatory diseases

Publications (2)

Publication Number Publication Date
AU2012294342A1 AU2012294342A1 (en) 2014-03-06
AU2012294342B2 true AU2012294342B2 (en) 2017-07-27

Family

ID=47669232

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012294342A Active AU2012294342B2 (en) 2011-08-10 2012-08-09 Methods and compositions for the treatment of autoimmune and inflammatory diseases

Country Status (10)

Country Link
US (3) US9879092B2 (enExample)
EP (1) EP2741771B1 (enExample)
JP (1) JP6253580B2 (enExample)
KR (2) KR102221068B1 (enExample)
CN (1) CN104114184B (enExample)
AU (1) AU2012294342B2 (enExample)
CA (1) CA2844668C (enExample)
ES (1) ES2813415T3 (enExample)
RU (1) RU2639540C2 (enExample)
WO (1) WO2013023059A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
WO2013023059A2 (en) 2011-08-10 2013-02-14 Lankenau Institute For Medical Research Methods and compositions for the treatment of autoimmune and inflammatory diseases
CA2884704C (en) 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
US10273301B2 (en) 2013-12-24 2019-04-30 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
AU2015243261B2 (en) * 2014-04-10 2020-06-25 Lankenau Institute For Medical Research Methods and compositions for the treatment of ocular diseases and disorders
EP3722314A1 (en) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
PE20190115A1 (es) 2016-04-15 2019-01-16 Immunext Inc Anticuerpos vista antihumanos y su uso
WO2018213331A1 (en) * 2017-05-16 2018-11-22 Lankenau Institute For Medical Research Compositions comprising ligands to rhob protein and the uses thereof
KR102276941B1 (ko) * 2018-07-03 2021-07-14 서울대학교산학협력단 류마티스 관절염 치료용 펩티드 및 그의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962672A (en) * 1998-09-18 1999-10-05 Isis Pharmaceuticals Inc. Antisense modulation of RhoB expression

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4116793A (en) * 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
EP1027042A4 (en) 1997-09-29 2004-08-18 Bristol Myers Squibb Co FARNESYL PROTEIN TRANSFERASE INHIBITORS
US6458783B1 (en) * 1997-09-29 2002-10-01 Bristol-Myers Squibb Company Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase
US20050032733A1 (en) 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US6979556B2 (en) 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
US7795218B2 (en) 2001-04-12 2010-09-14 Bioaxone Therapeutique Inc. ADP-ribosyl transferase fusion variant proteins
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1537140B1 (en) 2001-11-07 2013-01-02 Agensys, Inc. Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
WO2005017160A2 (en) * 2003-08-13 2005-02-24 Children's Hospital Medical Center Mobilization of hematopoietic cells
JP4967137B2 (ja) * 2005-04-18 2012-07-04 国立大学法人浜松医科大学 癌治療用組成物
US20070213354A1 (en) * 2006-03-08 2007-09-13 Amplimed Corporation Compositions and Methods for the Treatment of Multiple Sclerosis
RU2489166C2 (ru) * 2006-04-09 2013-08-10 Джинентех, Инк. Применение антитела для лечения аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
JP5354634B2 (ja) * 2007-01-25 2013-11-27 国立大学法人大阪大学 ヒトａｂｈ８タンパク質、それをコードする遺伝子、およびこれらの治療的又は診断的用途
EP2221063A1 (en) * 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
JP5941841B2 (ja) * 2009-05-26 2016-06-29 アイカーン スクール オブ メディシン アット マウント サイナイ 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用
WO2013004551A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
WO2013023059A2 (en) 2011-08-10 2013-02-14 Lankenau Institute For Medical Research Methods and compositions for the treatment of autoimmune and inflammatory diseases
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
AU2015243261B2 (en) * 2014-04-10 2020-06-25 Lankenau Institute For Medical Research Methods and compositions for the treatment of ocular diseases and disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962672A (en) * 1998-09-18 1999-10-05 Isis Pharmaceuticals Inc. Antisense modulation of RhoB expression

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GREENWOOD, J. et al., 'Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis', The FASEB Journal. 2003, Vol. 17, pages 905-907 *
SANTOS-BREDARIOL, A.S. et al., ‘Small GTP-binding protein RhoB is expressed in glial Muller cells in the vertebrate retina’, The Journal of Comparative Neurology. 2006, Vol. 494, pages 976-985 *

Also Published As

Publication number Publication date
KR20200042013A (ko) 2020-04-22
KR102101478B1 (ko) 2020-04-16
JP2014529590A (ja) 2014-11-13
EP2741771B1 (en) 2020-04-29
EP2741771A2 (en) 2014-06-18
RU2639540C2 (ru) 2017-12-21
EP2741771A4 (en) 2015-04-15
AU2012294342A1 (en) 2014-03-06
WO2013023059A2 (en) 2013-02-14
JP6253580B2 (ja) 2017-12-27
ES2813415T3 (es) 2021-03-23
US12545744B2 (en) 2026-02-10
US20140227279A1 (en) 2014-08-14
US20210040230A1 (en) 2021-02-11
KR20140067027A (ko) 2014-06-03
RU2014106933A (ru) 2015-09-20
CN104114184B (zh) 2017-04-19
US9879092B2 (en) 2018-01-30
CN104114184A (zh) 2014-10-22
CA2844668A1 (en) 2013-02-14
US20180094076A1 (en) 2018-04-05
WO2013023059A3 (en) 2013-04-04
CA2844668C (en) 2021-03-09
KR102221068B1 (ko) 2021-02-25

Similar Documents

Publication Publication Date Title
US12545744B2 (en) Anti-RhoB antibodies for the treatment of autoimmune and inflammatory diseases
RU2757813C2 (ru) Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение
CN116903727A (zh) 具有和不具有t细胞抑制蛋白的april和baff抑制性免疫调节蛋白及其使用方法
US12247069B2 (en) Use of TGF-alpha polypeptide or anti-TGF-alpha antibodies for the treatment of diseases and disorders
JP7032313B2 (ja) 抗ｐｄ－１抗体およびその使用
WO2012098238A1 (en) Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists
JP7783183B2 (ja) 自己免疫障害における抗ｂｃｍａ治療
WO2010132872A1 (en) Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists
US20230242674A1 (en) Compositions comprising antibodies to human ido-2
AU2018350372A1 (en) Method
CN119013309A (zh) 靶向pd-l1和cd40的抗原结合蛋白及其制备和应用
AU2016298108B2 (en) Methods and compositions for the treatment of immunomodulatory diseases and disorders
TW202206099A (zh) 藉由併用抗人類Fn14抗體及免疫檢查點抑制劑預防或治療癌症之醫藥組合物及方法
CA2992145C (en) Methods and compositions for the treatment of immunomodulatory diseases and disorders
EA050324B1 (ru) Терапия антителами против bcma при аутоиммунных расстройствах

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)